The first cases of what were postulated to be autosomal recessive (AR) CGD were described a year after that in 1968.2 The disease is estimated to occur in approximately 1 of 100,000 to 1 of 200,000 births,3–9 with the incidence differing among ethnic groups.8 Patients with CGD have defects in nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, which has membrane-associated (eg, gp91-phox and p22-phox) and cytosolic components (eg, p47-phox and p67-phox). This evidence concerns the gene CYBB and chronic granulomatous disease.